Knowledge Management as a Pharmaceutical Quality System Enabler: How Enhanced Knowledge Transfer Can Help Close the ICH Q10 to ICH Q12 Gap
Martin J Lipa,Anne Greene,Nuala Calnan,Martin J. Lipa
DOI: https://doi.org/10.5731/pdajpst.2020.011825
2020-07-16
PDA Journal of Pharmaceutical Science and Technology
Abstract:Knowledge management (KM) is identified in ICH Q10 (<i>Pharmaceutical Quality System</i>), as a key enabler to the pharmaceutical quality system (PQS). ICH Q8 (<i>Pharmaceutical Development</i>), ICH Q11 (<i>Development and Manufacture of Drug Substances</i>), and ICH Q12 (<i>Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management</i>) each build on the expectation that knowledge will be managed effectively in order to support and improve the product and process across the pharmaceutical product life cycle. However, in spite of the fact that KM was introduced in ICH Q10 over 10 years ago, there is ample evidence that it is not yet a mature discipline within the biopharmaceutical sector, and the authors suggest that this could hinder full realization of the potential benefits of ICH Q8, ICH Q11, and ICH Q12. The Pharmaceutical Regulatory Science Team (PRST), a research team based at the Dublin Technological University (TU Dublin) in Ireland, has been conducting research on KM for several years, and this paper presents the next phase in this research. Specifically, the focus of this current research was to explore ways to offer practical solutions to improve the management of knowledge across the pharmaceutical product life cycle, starting with a focus on enhancing knowledge transfer during technology transfer projects. The typical challenges associated with ineffective knowledge transfer were presented and the high-level requirements needed to address these were identified through the research. From these requirements, a four-step framework was developed as a systematic means to enhance knowledge transfer. Accompanying the framework was a KM toolkit consisting of a range of KM practices (tools, processes, and behaviors) to facilitate more effective knowledge flow during technology transfer. It was then illustrated how such a framework can be extended across the entire pharmaceutical product life cycle, supporting the advancement of KM from an <i>enabler</i> in ICH Q10 to a <i>key consideration</i> (both technical and regulatory) in ICH Q12.